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Abstract
Breast cancer mortality rates have shown only modest improvement despite the advent of
effective chemotherapeutic agents which have been administered to a large percentage of
women with breast cancer. In an effort to improve breast cancer treatment strategies, a
variety of mathematical models have been developed that describe the natural history of
breast cancer and the effects of treatment on the cancer. These models help researchers to
develop, quantify, and test various treatment hypotheses quickly and efficiently. The present
review discusses several of these models, with a focus on how they have been used to
predict the initiation time of metastatic growth, the effect of operative therapy on the growth
of metastases, and the optimal administration strategy for chemotherapy.
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Introduction
Breast cancer mortality rates across the entire population
in the USA have remained almost unchanged since 1970
[1]. In terms of numbers, it is estimated that 43300 women
died of breast cancer in the USA in 1999 [2]. Those who
succumbed to this disease did so as a consequence of
metastatic dissemination or the treatment of metastasis. A
large percentage of these women were treated with cyto-
toxic chemotherapy, with drugs that are demonstrated to
be effective against breast carcinoma cells both in vitro
and in vivo. Nevertheless, despite being treated with the
optimal doses at the optimal schedule, a significant per-
centage of women will relapse and die. For example, recur-
rence-free and survival rates at 10 years for women receiv-
ing polychemotherapy, for all ages, as estimated in the
Oxford Overview, were 44 and 51.3%, respectively [3].
This leads us to ask several questions. First, why are these
treatments unable to cure a large percentage of women?
Is it the result of cells that are resistant, either kinetically or
by means of clonal evolution, to the drugs? Is it a problem
of inefficient delivery to the tumor cells or a problem that
pertains to the tumor microenvironment? A second ques-
tion, undoubtedly related to the first set of questions, is
why does breast cancer continue to recur up to 20 years
after treatment of the primary tumor [4–10].http://breast-cancer-research.com/content/2/6/430
One discipline that can be helpful in answering the ques-
tions posed above is mathematical modeling. It has been
observed that trial and error manipulation of cancer treat-
ment can be an inefficient method of understanding and
developing treatment strategies [11,12••]. The use of
mathematical models can aid researchers by explaining
why some strategies fail; by suggesting refinements to
current clinical approaches; and, finally, by suggesting
alternative treatment strategies based on mathematical
models that are derived from both known and hypothe-
sized physiologic phenomena. Furthermore, many varia-
tions in the alternative strategies can be tested rapidly in
silico (on the computer), to determine their effectiveness
in a clinical setting. Although modeling strategies cannot
replace experimental and clinical results, they can both
eliminate some treatment strategies and suggest alterna-
tive strategies that may not be apparent just from trial and
error manipulation.
Modeling the natural history of breast cancer
Developing a better understanding of the natural history of
breast cancer via mathematical models may suggest more
effective methods of screening and treatment, and may
enable us to answer some of the above questions. A
variety of models have been proposed for the natural
history of breast cancer. They include models by Speer et
al  [13•], Norton and Simon [14•,15••,16], Spratt et al
[17,18], and Koscielny et al [19••], to list just a few.
The Gompertz model has been the mainstay for models of
solid tumors, including breast cancers, for a considerable
period of time. The Gompertz model is a modification of
exponential growth, with the addition of a decreasing
growth rate over time. This decelerated growth causes the
cancer to asymptotically approach a limiting size, referred
to as its carrying capacity. This limited growth is attributed
to several factors, including hypoxia and the lack of nutri-
ents. The origin of this model is a variety of in vivo studies
in which the Gompertz equation most accurately
describes the growth dynamics of the tumor [20]. Using
data from Bloom et al [21] on the natural history of breast
cancer in untreated women admitted to the Middlesex
Hospital, London, UK, from 1805 to 1933, Norton and
Simon [14•,15••] and Spratt et al [17] used this model to
describe the data.
Speer et al [13•] observed that the subclinical duration of
growth given by the original Gompertz growth equation,
using a range of parameter values similar to those used by
Sullivan and Salmon [22], is too short (approximately 4
months). Also, Heuser et al [23] reported that clinical data
derived from serial mammograms indicated that nine out
of 109 untreated breast cancers measured over a 1-year
period showed no growth, and the original Gompertz
equation could not account for this observed dormant
phase. Thus, they developed a modified Gompertzian
model with a stochastic growth rate. This allows for a
stepwise growth pattern, with the possibility of dormant
phases. In a continued effort to verify this modified model
of Gompertz growth with dormant stages and growth
spurts, Retsky et al [24] reviewed the literature and
described a variety of clinical cases in which the traditional
exponential or Gompertz model was not consistent with
the data.
If the current hypotheses regarding angiogenesis and the
development of a tumor microvasculature are correct (see
Holmgren et al [25] and Folkman [26–28]), then models
will need to include some type of dormant phase if they
are to accurately account for the complete natural history
of the cancer. In fact, Spratt et al [17] indicated that,
although the original Gompertz model can give a good
approximation to clinical tumor growth over the short term,
the growth rate of the cancer is more likely to be stochas-
tic over the full history of the cancer. This allows for
various growth patterns, including dormancy.
Although initially it may seem that it will make little differ-
ence whether either the original Gompertz model or the
modified Gompertz model is used to describe the natural
history of breast cancer, a quick comparison of the model-
ing results in the different papers indicates that there are
significant differences. For example, using the same data
sets Norton [29] (using the original Gompertz growth
model) predicted a 2.25-year median preclinical growth
phase, whereas Speer et al [13•] (using the modified
Gompertz growth model) determined it to be approxi-
mately 8 years. (Also see the letter by Retsky et al [30] in
reference to the above-mentioned paper by Norton.) 
One of the major impediments to the modeling of breast
cancer is our lack of data on its natural history. This makes
it difficult to determine whether the growth of a primary
breast tumor is a continuous function, or whether it is
interrupted by periods of dormancy. Most of the data avail-
able comes from serial mammograms. The problem with
this is that there are usually only two data points (the esti-
mated size of the cancer when it was diagnosed and the
estimated size from a previous mammogram that is
reviewed retrospectively) [17,18]. Such a sparse amount
of data leads to an indistinguishability problem between
the various proposed models (ie biologically different
models can describe the same data set equally well). Con-
sider, for example, the exponential equation. Spratt et al
[17] determined from the mammogram data that the
median doubling time is 260 days for breast tumors at
detectable levels. Extrapolating back from the approximate
detectable size of 109 cells, this would indicate that the
tumor was initiated about 21 years prior, which seems
rather long. In fact, if we consider one of the slower
growing breast cancers that they observed, with a dou-
bling time of 7051 days, then the tumor would have beenBreast Cancer Research    Vol 2 No 6 Clare et al
initiated 578 years prior, which is of course absurd. On
the basis of this, we should rule out exponential growth as
a viable model of the full natural history of breast cancer.
Modeling breast cancer metastasis
Using the various models of the natural history of breast
cancer, researchers have then modeled the initiation time
of metastatic growth; the effects of screening on metas-
tases; the effects of surgery on recurrence; and methods
of effective adjuvant chemotherapy. These models are
used to help address the questions posed in the introduc-
tion to this paper.
Estimated initiation time of metastatic growth
The ability to determine the initiation time of metastatic
growth would enable us to determine the likelihood of a
patient having metastatic recurrence. As should be
expected, the predicted initiation time relies significantly on
the model of the cancer’s natural history. For example, if the
model predicts there will be metastatic growth with an
early initiation time relative to the diagnosis of the primary
(ie there is a high probability that the metastasis has
already occurred by the time the primary is diagnosed),
then the treatment strategy would be designed differently
than if the metastasis were unlikely to have been initiated.
One particular model that considers this question was
developed by Koscielny et al [19••]. They developed a
model to determine the age of metastases at primary
tumor diagnosis; the volume of the primary tumor when
the metastasis is initiated; the duration of metastatic
growth; and the delay between primary diagnosis and
appearance of the metastasis. Two main hypotheses play
a role in how they developed their model. The first hypoth-
esis is that the metastatic growth rate is proportional to
the size of the tumor from which it was derived. The
second is that the probability of metastasis is related to
the primary tumor doubling time. Using their model, they
observed that their data showed that the metastatic initia-
tion occurred at a tumor volume of the primary lesion that
was only slightly smaller than that at the time of tumor
diagnosis. This is in contrast to the findings of others who
used an exponential growth model, with the doubling time
of the primary tumor equal to that of the metastatic
growth, and predicted that metastatic initiation occurs
very early in the development of the primary tumor.
Koscielny et al [19••] concluded that the metastatic dou-
bling time is faster than that of the primary (specifically,
metastatic growth is about 2.2 times faster than that of the
primary); the number of cells needed for metastatic initiation
is greater than a single cell; tumor growth is not exponential
over the life of the tumor; and growth duration of metas-
tases is approximately 3.8 years, which is much shorter than
the previously determined duration of about 17 years (deter-
mined using exponential growth and equivalent doubling
times for the primary and metastasis). Following these con-
clusions, they estimated that approximately 30% of patients
have metastases that are less than 1 year old, and therefore
annual screening would be expected to result in a 30%
decrease in the incidence of metastasis. This prediction is in
accord with the results of breast cancer screening trials
including the Health Insurance Plan trial, the Swedish
Centers Combined and Edinburgh Trial ([31] and refer-
ences therein), which showed a decrease in mortality of
approximately 30% for women aged 50–69 years who
underwent screening mammography.
Effects of surgery on metastasis
Retsky  et al [12••] observed a statistically significant
bimodal distribution for local and distant, but not contralat-
eral breast cancer relapse using the Milan National
Cancer Institute database of 1173 breast cancer patients.
This distribution includes a sharp peak of relapse at
18 months and another broad peak at 60 months after
surgery. They attributed this bimodal distribution to the
effects of surgery on promoting metastatic growth.
To help understand this previously unobserved bimodal
recurrence pattern, they developed a stochastic model to
attempt to simulate (by Monte Carlo simulations) the clini-
cal results. The model consists of a component to
describe the primary tumor growth, based on the model of
Speer et al [13•] (see the previous section). This is used
to describe the release, via a stochastic mechanism, of
metastatic cells once the primary tumor is vascularized.
The other main component of the model describes
metastatic growth and detection, and has three main
growth stages. The first stage is a dormant single metasta-
tic cell phase. The second is an avascular stage modeled
by Gompertzian growth, with a limiting size of approxi-
mately 105 cells (or about 0.1–0.5 mm in diameter). The
size is limited by the fact that the cells must be nourished
by diffusion of nutrients from the existing vasculature.
Cells in this stage may remain viable but nongrowing
indefinitely. Proangiogenic factors elaborated by the tumor
or a downregulation of antiangiogenic factors produced in
the stroma, or a combination of both, may result in the
induction of a neovasculature that will nourish the metasta-
tic deposit and enable regrowth. This change accounts for
entry into the third stage – a vascular stage that is also
modeled by Gompertzian growth with a limiting size of
approximately 1012 cells. The transition between these
three phases is considered stochastic.
One of the interesting features of the model is that it allows
for an increased progression of metastatic cells to the
avascular and the vascular stages immediately after
surgery. This was hypothesized to be due to a reduction in
levels of tumor angiogenesis factor (produced by the
primary tumor) after surgery, allowing angiogenesis to
occur at the metastasis and thus allowing rapid growth ofthe metastatic lesion. The model without the possibility of
stimulation due to the removal of the primary tumor could
not produce the bimodal distribution of relapses observed
clinically, and only the second peak was observed.
However, when the model did account for stimulation of
the metastatic cells to stage 2 (avascular) or 3 (vascular)
due to the surgical removal of the primary tumor, then the
bimodal distribution of relapses similar to that seen in the
clinical data was observed. Retsky et al attributed the first
peak of the bimodal recurrence distribution to metastases
in the first two stages before surgery that are then pro-
moted (due to angiogenesis) to the second or third stages.
Adjuvant therapy
Kinetic resistance
One of the early models that attempted to describe effective
adjuvant chemotherapy is that of Norton and Simon
[14•,15••]. They assumed that all tumor growth, tumor
regression, and tumor regrowth is Gompertzian. The initial
response of a tumor to chemotherapy is cell death or
depopulation. According to Gompertzian kinetics, as the
tumor becomes smaller its growth fraction increases, and it
regrows at a faster rate. At some point the rate of cell kill
may equal the rate of cell repopulation, and the cell popula-
tion will approach an asymptotic limit. If the asymptotic limit
after chemotherapy is always greater than one cell, a cure
will never be effected. However, if it is less than one cell, a
cure can reasonably be expected. The implication for treat-
ment is that the only way to effect a cure is the absolute
eradication of every viable micrometastatic cell. Therefore,
Norton and Simon suggested that, when treating
micrometastases, high-dose, short-duration treatment
(single drug or combination) followed sequentially by a non-
cross-resistant treatment may be preferable to prolonged
duration, low-dose therapy. This treatment strategy chal-
lenges the log-kill hypothesis of Skipper et al [32•], which
suggests that cell kill is proportional to the tumor size.
Clonal resistance
Rather than kinetic resistance, the resistance of cancer
cells to chemotherapeutics may be a consequence of
clonal selection. The resistance of bacteria to bacterio-
phages is a random event, as demonstrated by Luria and
Delbruck [33••]. A study reported by Law [34], which used
an adaptation of the Luria and Delbruck method, con-
cluded that the resistance of the murine leukemia cell line
L1210 to A-methopterin, a folic acid antagonist, was also
secondary to mutations occurring at random. The
Goldie–Coldman model [35] was the first major attempt
to place the theory of the evolution of drug resistance by
clonal selection into a sound mathematical basis. One of
the assumptions of their model is that at each cell division
of a nonmutant tumor cell, there exists a fixed nonzero
probability that any new daughter cell will be a resistant
mutant. By the time a tumor is detected, that is, by the
time it reaches 109 cells, the Goldie–Coldman model
estimates that drug-resistant mutants are present. Also,
with an increasing population, the probability that a double
mutant is created at random is also increased. Given
these assumptions, the optimal way to administer
chemotherapy would be to alternate two or more equally
effective drugs as rapidly as possible to prevent clonal
resistance [36••].
In a similar manner, Panetta [37] defined a model that
describes a heterogeneous tumor population and the
effects of chemotherapy. The model is used to determine
conditions on when treatment should be switched from
one drug (or combination of drugs) to a second noncross-
resistant drug (or combination of drugs). This condition is
related to the ratio of resistant to sensitive cells. The
model indicates that the more effective the treatment is,
the sooner it will be necessary to switch to the second
noncross-resistant treatment.
Tumor dormancy
More recently Retsky and coworkers [12••,38], Demicheli
et al [39], and Swartzendruber et al [40] hypothesized
that adjuvant therapy may only benefit those patients who
are not cured by local therapy and who would relapse
under the first peak of the frequency of the relapse curve
(at around 18 months). Smaller tumors with good prog-
nostic factors tend to relapse under the second peak of
the frequency of the relapse curve (at around 5 years).
Therefore, early detection of tumors could make adjuvant
chemotherapy less effective because the metastatic
growth has a good chance of being in an avascular
dormant stage that is kinetically resistant to adjuvant
chemotherapy administered immediately after an opera-
tion. Demicheli et al [41•] demonstrated the above hypoth-
esis by showing that cyclophosphamide, methotrexate,
fluorouracil (CMF) therapy can reduce the risk of metasta-
tic recurrence when compared with surgery alone, but
only for patients with recurrences that occur within about
the first 3 years. This supports the dormancy hypothesis of
Retsky et al [12••]. They suggested that either an angio-
genesis-inhibiting drug such as angiostatin or the reintro-
duction of chemotherapy at a later time need to be
discussed as alternative treatment strategies.
Another interesting observation made by Demicheli et al
[41•] is that CMF does not shift the bimodal hazard func-
tion to the right (thus just postponing relapse), but rather
lowers the peaks. This implies that CMF adjuvant therapy
can ‘cure’ some patients rather than just postpone the
recurrence. This idea challenges the view that adjuvant
chemotherapy only prolongs survival transiently, and no or
very few patients are cured.
Conclusion
How do the various models help us to address the ques-
tions posed in the first two paragraphs? What are the
http://breast-cancer-research.com/content/2/6/430implications of the various cytokinetic models for treat-
ment? To illustrate how mathematical models have been
used to design clinical trials, two clinical trials for the adju-
vant treatment of breast cancer are briefly discussed.
One of the relatively early clinical trials for women with
node-positive breast cancer compared the Norton–Simon
model (four courses of adriamycin followed by eight
courses of CMF [‘sequential’]) with the Goldie–Coldman
model (two courses of CMF alternated with one course
adriamycin for a total of 12 courses [‘alternating’]) [42]. The
5-year relapse-free survival for the sequential administration
arm was 61% and for the alternating administration was
38% (P = 0.001). The corresponding figures for 5-year
overall survival were 78 and 62%, respectively. The benefit
of sequential therapy was observed in all patient subsets.
A clinical trial was designed by the International Breast
Cancer Study Group, trial VI, in order to try to examine the
possibility that chemotherapy reintroduced at times after
the completion of an early postoperative course would be
able to treat those cells that have emerged from dormancy
[43]. Premenopausal women with node-positive breast
cancer (n = 1554) were randomly assigned in a 2 × 2 fac-
torial design to receive the following: CMF for six consec-
utive courses on months 1–6 (CMF × 6); CMF × 6 plus
three single courses of reintroduction CMF on months 9,
12 and 15; CMF for 3 consecutive courses on months
1–3 (CMF × 3); or CMF × 3 plus three single courses of
reintroduction CMF given on months 6, 9 and 12.
Patients who were treated with reintroduction chemother-
apy had a 5-year disease-free survival rate of 58 ± 2%,
compared with 55% ± 2% for those who did not receive
reintroduction (hazards ratio 0.86, 95% confidence inter-
val 0.73–1.01; P = 0.07). The overall survival figures were
76% ± 2% and 75% ± 2%, respectively. Although reintro-
duction showed a trend toward a therapeutic effect, this
difference was not statistically significant. Patients ran-
domized to receive reintroduction had an estimated reduc-
tion of relapse of 14% whether the initial chemotherapy
consisted of three cycles or six cycles.
Although this study does not definitively support the
Retsky–Demicheli model, it could be due to the design of
the study. Women who were eligible for the International
Breast Cancer Study Group trial VI ranged across the
staging spectrum from IIA to IIIA. The benefit of reintro-
duction may have accrued disproportionately to those
women who had primary tumors that were less than or
equal to 2.0 cm (T1) with one to three positive nodes, and
it may be enlightening to re-examine this subset of patients
specifically. Also to be considered when examining the
results of the trial are the consequences of prolonged
chemotherapy. Compliance with chemotherapy trials is
inversely associated with toxicity and duration of treat-
ment. Among the patients assigned to receive reintroduc-
tion after six initial courses, 85% started and 75% com-
pleted the reintroduction as scheduled in months 9, 12,
and 15. This decreased compliance may have diluted the
therapeutic effect of the reintroduction regimen in prac-
tice. This suggests the possibility that a cytostatic agent,
such as an angiogenesis inhibitor, which could be admin-
istered chronically with less toxicity, might be better toler-
ated than an intermittent cytotoxic agent.
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